Global High-Priority Regulatory Events — April 07, 2026

07-04-2026

Crane NXT, Co.'s DEF 14A proxy statement seeks stockholder ratification of Deloitte & Touche LLP as independent auditors and an advisory 'Say-on-Pay' vote on 2025 NEO compensation. Corporate 2025 annual incentive performance achieved a weighted 94% payout, with revenue at 129% of target ($1,568.6M) but adjusted operating profit at 79% ($335.8M) and adjusted free cash flow at 89% ($213.5M). The Security and Authentication Technologies segment reached 100% payout, driven by revenue at 193% of target ($722.0M) but offset by adjusted operating profit at 77% ($147.8M) and free cash flow at 53% ($129.5M).

• ·Corporate incentive metrics weighted 25% revenue / 50% adjusted operating profit / 25% adjusted free cash flow; excludes certain acquisition and restructuring costs.
• ·Security and Authentication Technologies metrics weighted similarly for Mr. Keayes.
• ·NEO target bonus percentages unchanged from 2024 except Mr. Saak increased to 110% of base salary; Ms. DiMaurizio ineligible for 2025 annual incentive.
• ·Exchange rates: 1.3445 USD/GBP for 2025, 1.2521 USD/GBP for 2024.
• ·Audit Committee approved Deloitte budget for 2026 and reappointment on February 17, 2026.

07-04-2026

Pioneer Bancorp, Inc. issued a definitive proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026 at 9:00 a.m. local time, soliciting votes for the election of three directors, ratification of Bonadio & Co., LLP as independent registered public accounting firm for the year ending December 31, 2026, and a non-binding advisory resolution on Named Executive Officers' compensation. As of the record date March 23, 2026, there were 25,076,801 shares of common stock outstanding, with Pioneer Bancorp, MHC beneficially owning 14,287,723 shares (57.0%) and M3 Funds, LLC owning 1,884,081 shares (7.5%). The Board unanimously recommends voting 'FOR' all proposals, and no directors or executive officers have pledged shares.

• ·Record date for voting eligibility: March 23, 2026
• ·Virtual annual meeting access: https://www.cstproxy.com/pioneerbancorp/2026 (requires 12-digit control number)
• ·Registration deadline for beneficial owners to attend virtually: 5:00 p.m. ET on May 14, 2026
• ·Conference call for listening: +1-800-450-7155 (U.S./Canada toll-free) or +1-857-999-9155 (international), code 4849410#
• ·Articles of Incorporation limit voting rights for holders >10% (except Pioneer Bancorp, MHC)

07-04-2026

Target Hospitality Corp.'s DEF 14A proxy statement seeks stockholder approval for the election of six director nominees at the annual meeting on May 21, 2026. It highlights strong 2025 fiscal year performance, including $320.6 million in total revenue, $53.2 million in Adjusted EBITDA, $66 million in Discretionary Cash Flow, $0 net debt, and ~$740 million in new multi-year awards secured since February 2025, supported by 16,991 beds across 29 communities. The company emphasizes robust corporate governance, stockholder outreach engaging over 80% of shares, and a skilled board with expertise in leadership, operations, finance, and strategy.

• ·Annual meeting scheduled for May 21, 2026
• ·Fiscal year ended December 31, 2025
• ·Board competencies: 6 directors with advanced/expert leadership/business head/administration, business operations, corporate governance, finance/capital allocation/risk management, strategy; 5 with safety, human resources/talent management, board/committee experience; 4 with financial expertise/literacy, government/public policy, M&A/capital markets; 2 with marketing/sales, cybersecurity/IT; 1 with AI data centers/critical infrastructure

07-04-2026

Kiora Pharmaceuticals closed a private placement on April 6, 2026, providing up to $24 million in gross proceeds, including $5.0 million upfront funding from sole investors Perceptive Advisors (new) and ADAR1 Capital Management, with up to an additional $19 million upon exercise of milestone-based warrants. Proceeds will support general corporate purposes, business operations, strategic business development, and ongoing R&D for retinal disease therapies like KIO-301 and KIO-104. The transaction was priced at-the-market under Nasdaq rules with no placement agent engaged.

• ·Tranche A-1 warrants: initial 9-month term, reduces to 30 days upon strategic transaction expanding market opportunity.
• ·Tranche A-2 warrants: initial 4-year term, reduces to 30 days upon any asset completing Phase 3 enrollment.
• ·Pre-funded warrants issued in lieu of common stock at $2.543 minus $0.0001 exercise price.
• ·Company to file SEC registration statement for resale of shares and warrant shares.
• ·Transaction closed April 6, 2026, under Section 4(a)(2)/Regulation D; securities unregistered.

07-04-2026

The Travelers Companies, Inc. (TRV) filed its DEF 14A Proxy Statement on April 7, 2026, for the Annual Meeting of Shareholders on May 20, 2026, recommending votes FOR electing eight director nominees (7 independent, average age 63, average tenure 6 years, 50% diverse), ratifying KPMG LLP as independent auditors for 2026, approving executive compensation on a non-binding basis, and amending the 2023 Stock Incentive Plan, while recommending AGAINST two shareholder proposals on climate-related reporting and an independent board chairman. Governance highlights include all non-Executive committees comprised of independent directors, an independent Lead Director, regular executive sessions, and non-employee directors receiving over 50% of compensation in deferred stock units. Executive compensation emphasizes pay-for-performance, with CEO mix of 5% base salary, 32% annual cash bonus, and performance-based equity (mix incomplete in filing excerpt).

• ·Annual Meeting: May 20, 2026, 9:00 a.m. EDT at Hartford Marriott Downtown, 200 Columbus Boulevard, Hartford, CT 06103 (virtual option possible).
• ·Record date: March 23, 2026.
• ·Proxy voting deadlines: 11:59 p.m. EDT on May 19, 2026 (record holders/brokers); May 18, 2026 (401(k) plan).
• ·Shareholder proposals: ITEM 5 – Report on Climate-Related Pricing and Coverage Decisions; ITEM 6 – Independent Board Chairman.

07-04-2026

Legato Merger Corp. III is seeking shareholder approval via proxy for an Extension Proposal to amend its memorandum and articles, extending the deadline to complete its initial business combination with Einride beyond May 8, 2026, to avoid liquidation and redemption of public shares. Officers and directors, owning 4,356,475 ordinary shares (16.3% of outstanding shares), intend to vote in favor of the Extension and Adjournment Proposals. Public shareholders retain redemption rights at an estimated $11.00 per share, with potential Insiders' purchases to reduce redemptions, though no such plans are committed.

• ·Extension Proposal requires special resolution (at least two-thirds majority of votes cast).
• ·Adjournment Proposal requires ordinary resolution (simple majority of votes cast).
• ·If Extension not approved, liquidation by May 8, 2026, with public shares redeemed from Trust Account (net of taxes and up to $100,000 dissolution expenses).
• ·Company may seek further extensions if deemed in best interests.
• ·Insiders may purchase Public Shares at <= $11.00/share pre/post-meeting to reduce redemptions, but such shares would not be voted.

07-04-2026

Healthcare Realty Trust Inc (HR) filed its DEF 14A proxy statement on April 7, 2026, providing XBRL-tagged disclosures on executive compensation for Principal Executive Officer (PEO) Scott and Meredith Moore, covering equity awards, fair value changes, vesting, and dividends from 2021-2025 with no specific performance declines or improvements quantified. The filing details the company's insider trading policy, including quarterly blackouts and pre-clearance requirements, and confirms the Board's February 2026 annual review of director independence under NYSE-aligned standards. No operational or financial performance metrics are reported, maintaining a governance-focused disclosure.

• ·Insider trading policy prohibits trading on material nonpublic information, imposes quarterly blackouts starting one week before quarter-end through one trading day after earnings release, requires pre-clearance for directors/officers, and bans short sales, options, hedging, and pledging.
• ·Director independence review conducted by Nominating and Corporate Governance Committee and Board in February 2026, using categorical standards consistent with NYSE requirements.
• ·Corporate Governance Principles available at www.healthcarerealty.com under Investor Relations.

07-04-2026

Energy Transition Special Opportunities (formerly Climate Transition Special Opportunities SPAC I) filed an amended S-1/A registration statement on April 7, 2026, for an IPO of Firm Units targeting $150,000,000 in gross proceeds (implied 15 million units at $10 each), with an over-allotment option for up to 2,250,000 additional units. Proceeds from Firm Units and Private Placement will be deposited into a trust account, including a 4.0% deferred underwriting commission of $6,000,000 (up to $900,000 for Option Units). The Sponsor holds 5,750,000 Founder Shares issued for a total of $25,000, with warrants exercisable at $11.50 per share post-Business Combination.

• ·Warrants entitle holder to purchase one Ordinary Share for $11.50, exercisable 30 days after Business Combination, expiring five years after or upon redemption/liquidation
• ·Over-allotment Option exercisable within 45 days of Registration Statement effective date
• ·Company name changed from Climate Transition Special Opportunities SPAC I on September 15, 2025
• ·Founder Shares issued July 30, 2025, with 1-for-1.26605495295 share split on September 4, 2025; 75,000 transferred to director nominees

07-04-2026

Mistras Group, Inc. seeks shareholder approval at the 2026 Annual Meeting to amend its Amended and Restated 2016 Long-Term Incentive Plan by increasing authorized common shares by 1,700,000 to a total of 7,900,000 shares, approved by the Board on February 26, 2026. As of March 20, 2026, 260,957 shares remain available (resulting in 1,960,957 available if approved), with outstanding awards covering 2,160,058 shares and potential dilution of 11.5% based on 31,800,784 shares outstanding. The three-year average annual burn rate is 2.4%, and rejection would limit equity awards, forcing reliance on cash compensation.

• ·Board approval of Amendment: February 26, 2026
• ·Effective date if approved: May 19, 2026 (2026 Annual Meeting date)
• ·Plan expiration date: March 27, 2034
• ·Previous share increases approved: 2020 (to 3,700,000), 2022 (to 4,900,000), 2024 (to 6,200,000)
• ·Plan originally adopted: August 20, 2016
• ·Governance features: no repricing, no discounted options, minimum 1-year vesting (except non-employee directors), clawback policies, stock ownership guidelines
• ·NYSE rules require shareholder approval

07-04-2026

On April 1, 2026, Consolidated Water Co. Ltd. promoted Douglas Vizzini from Vice President of Finance to Executive Vice President and Chief Accounting Officer and entered into an employment agreement with him effective that date through December 31, 2027, with potential two-year extensions at the CEO's discretion. The agreement includes an annual base salary of $350,000, a targeted short-term incentive of 25% of base salary, annual RSU grants valued at 20% of base salary, and a monthly automobile allowance starting at $1,750. Termination provisions include severance equal to one year's base salary if not extended, immediate termination for cause, and provisions for incapacity or resignation with six months' notice.

• ·RSUs vest one-third annually over three fiscal years, subject to continued service.
• ·Severance of one year's base salary if CEO elects not to extend term.
• ·Termination for felony conviction or material harm (with 10-day cure period); resignation requires six months' notice.
• ·Incapacity provisions: duties relieved after 60 days, salary reduced to $1,000/year, full medical coverage until recovery; auto-termination after 12 months.

07-04-2026

07-04-2026

Teamshares Inc. and Live Oak Acquisition Corp. V (NASDAQ: LOKV) announced the filing of their joint registration statement on Form S-4 with the SEC on April 3, 2026, in connection with their proposed business combination, a key step toward Teamshares becoming publicly traded. The combined company is expected to operate as Teamshares Inc. and list on Nasdaq under ticker 'TMS', with closing anticipated in Q2 2026, subject to shareholder approval, SEC effectiveness, and other conditions. Teamshares, a tech-enabled acquiror of SMEs, operates subsidiaries with consolidated revenue of over $400 million across over 40 industries and 30 states.

• ·S-4 registration statement filed April 3, 2026
• ·Business combination previously announced November 14, 2025
• ·Teamshares founded in 2019
• ·Acquires SMEs with $0.5 to $5 million EBITDA
• ·Live Oak V address: 4921 William Arnold Road, Memphis, Tennessee, 38117

07-04-2026

The Brink’s Company entered into an Amended and Restated Credit Agreement on March 31, 2026, providing a $1.225B refinanced senior secured term loan facility, $1.025B delayed draw term loan commitments, a $1.0B revolving credit facility, and up to $600M in additional upsize revolver commitments primarily to fund its pending acquisition of NCR Atleos Corporation, refinance NCR Atleos indebtedness, and support general corporate purposes. The facilities mature on March 31, 2031, with borrowings bearing interest based on base rate or Term SOFR plus an Applicable Percentage, subject to financial covenants including a maximum Consolidated Net Secured Leverage Ratio of 3.50 to 1.00 (with a 0.50 step-up for acquisitions) and a minimum Consolidated Interest Coverage Ratio of 2.50 to 1.00. No declines or flat performance metrics are reported, as this filing details new financing arrangements replacing prior facilities on substantially equivalent terms.

• ·Facilities mature March 31, 2031, subject to springing maturity tied to specified indebtedness.
• ·Amended and Restated Credit Agreement amends 2017 Credit Agreement and replaces bridge financing from Morgan Stanley.
• ·Press release issued April 6, 2026, announcing the agreement (furnished under Regulation FD).

07-04-2026

S&T Bancorp, Inc. and S&T Bank entered into an amended and restated employment agreement with CEO Christopher McComish, effective January 1, 2026, for a four-year term with automatic annual renewals. The agreement sets a minimum annual base salary of $785,000, target annual bonus of 67% of base salary, and long-term incentive awards with target value of at least 100% of base salary (50% time-vesting, 50% time- and performance-vesting). It includes severance of 2x (or 3x within two years post-change in control) base plus target bonus, COBRA premiums for 24 (or 36) months, and other perks like up to $25,000 annual vehicle allowance and $25,000 legal fee reimbursement, plus one-year post-termination non-compete and non-solicit covenants.

• ·Employment agreement has a four-year initial term with automatic one-year renewals.
• ·Severance benefits conditioned on execution of a release of claims.
• ·Perpetual covenants for nondisclosure of confidential information and non-disparagement.
• ·Non-competition and non-solicitation covenants apply for one year post-termination.

07-04-2026

Ross Stores, Inc. filed its DEF 14A Proxy Statement for the virtual 2026 Annual Meeting of Stockholders on May 20, 2026 at 1:30 p.m. PDT, with a record date of March 24, 2026. Key proposals include electing 9 directors for one-year terms, approving the 2026 Equity Incentive Plan, an advisory vote on executive compensation, and ratifying Deloitte & Touche LLP as independent auditors for the fiscal year ending January 30, 2027. The filing includes standard pay versus performance disclosures for the Principal Executive Officer (PEO) and Non-PEO Named Executive Officers across fiscal years ending January 2022 through January 2026, though specific compensation values are not detailed in the provided content.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/ROST2026
• ·Voting methods available: Internet (www.ProxyVote.com), telephone (1-800-690-6903), or mail
• ·Proxy voting deadline: 11:59 p.m. ET on May 19, 2026
• ·Stockholder list available for inspection 10 days prior to meeting at 5130 Hacienda Drive, Dublin, CA 94568
• ·Pay vs. performance disclosures cover fiscal years 2022-2026 for PEO and Non-PEO NEOs, including metrics like vesting date fair value of equity awards and changes in fair value

07-04-2026

Patodia Properties Private Limited, a promoter group entity holding 84,70,000 shares (3.80%) in Choice International Limited, created a new pledge encumbrance on 2,60,000 shares (0.12% of total share capital) on March 30, 2026, comprising 2,50,000 shares with Aditya Birla Finance Limited as collateral for a Rs. 6,00,00,000 loan and 10,000 shares with SMFG India Credit Co Ltd. Post-event, their encumbered shares rise to 75,20,000 (3.38% of capital), representing 91.85% of their total holding, with the aggregate promoter group encumbrance at 1,44,20,000 shares (6.47% of capital). The funds are for personal use by the promoters.

• ·Pledge ratio (security cover): 2.78 (value of shares Rs. 16,03,75,000 against loan Rs. 6,00,00,000 for 2,50,000 shares)
• ·Encumbered shares exceed 50% of Patodia Properties Private Limited's holding: YES
• ·Encumbered shares exceed 20% of total share capital: NO
• ·Disclosure date: April 04, 2026; Filing date: April 07, 2026
• ·Total promoter group pre-event encumbrance: 1,41,60,000 shares (6.36%)

07-04-2026

Camlin Fine Sciences Limited has disclosed a Postal Ballot Notice dated April 3, 2026, seeking shareholder approval via remote e-voting to increase its authorized share capital from ₹21,50,00,000 (21 Crore 50 Lakh equity shares of ₹1 each) to ₹25,00,00,000 (25 Crore equity shares of ₹1 each), with consequent amendment to Clause V of the Memorandum of Association. The e-voting period commences on April 8, 2026, at 9:00 a.m. IST and ends on May 7, 2026, at 5:00 p.m. IST, with results to be announced by May 9, 2026. This is a standard corporate action with no associated financial performance metrics.

• ·Cut-off date for e-voting eligibility: Friday, April 3, 2026.
• ·Scrutinizer: Mr. J. H. Ranade of M/s. JHR & Associates.
• ·Company CIN: L74100MH1993PLC075361.
• ·Registered Office: In G.S. Point, Floor 2 to 5, CST Road, Kalina, Opp. University Campus, Santacruz (East), Mumbai – 400 098.

07-04-2026

Ankit Mehta, Promoter and Whole-time Director of ideaForge Technology Limited, created a pledge over 3,70,370 equity shares (0.85% of total share capital) on March 19, 2026, representing approximately 10% of his total holding of 36,86,964 shares (8.52%). The pledge was made to Neo Wealth Management Private Limited for personal financial requirements. This encumbrance carries invocation risks for shareholders with no offsetting positive developments disclosed.

• ·Disclosure reported to exchanges on April 06, 2026
• ·DIN: 02108289
• ·No prior encumbrances on these shares (Nil already encumbered)
• ·Encumbered shares <50% of promoter holding and <20% of total share capital
• ·No existing events/agreements pertaining to encumbrance

07-04-2026

Equilibrated Venture Cflow Pvt. Ltd., a promoter group entity holding 18,67,63,880 shares (20.53% of Paisalo Digital Limited's total share capital), disclosed the release of pledge on 40,00,000 shares (0.44%) on April 2, 2026, as collateral for loans from Cholamandalam Investment and Finance Company Limited. Post-release, their encumbered shares reduced to 7,49,09,002 (8.24%) from 7,89,09,002 (8.68%). While other promoters like Pro Fitcch Pvt. Ltd. and Pri Caf Pvt. Ltd. continue to hold minor encumbrances of 18,10,000 shares each (0.20%), several individual promoters such as Sunil Agarwal report zero encumbered shares.

• ·Disclosure reported on April 4, 2026, under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.
• ·Encumbrance was for collateral on loans taken by the company.
• ·Historical encumbrances include multiple pledges to entities like STCI Finance Ltd., IIFL Finance Limited, and others, with prior releases noted.

07-04-2026

Sanjay Dhir, promoter of Zenlabs Ethica Limited, confirmed on behalf of promoters and promoter group that NIL shares were pledged or encumbered as of March 31, 2026. The disclosure was made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, via a letter dated April 6, 2026. Promoter group entities include Preet Remedies Ltd., Harjinder Kaur, and Kulwant Kaur.

• ·Letter addressed to BSE Limited's Corporate Relationship Department and Audit Committee.
• ·Company CIN: L74900CH1993PLC033112
• ·Filing Date: April 07, 2026

07-04-2026

Adani Power Limited informed stock exchanges that a Board of Directors meeting is scheduled for April 29, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The trading window for dealing in company securities remains closed from April 1, 2026, and will re-open 48 hours after the results announcement. An investor/analyst call is planned for the same day to discuss the results and business outlook.

07-04-2026

RRE Ventures Acquisition Corp., a special purpose acquisition company (SPAC), filed an S-1 registration statement for an initial public offering of 25,000,000 units, each consisting of one Class A ordinary share and one-third of a warrant exercisable at $11.50 per share. Post-offering, and assuming no exercise of the underwriter's over-allotment option and surrender of 1,250,000 founder shares, the company will have 33,333,333 Class A ordinary shares and 15,343,333 warrants outstanding. The sponsor, RRE Sponsor LLC, initially invested $25,000 and holds founder shares, with 2,718,000 Class B shares sold to management team affiliates, third-party investors, and a consultant.

• ·Up to 1,250,000 founder shares subject to forfeiture depending on underwriter’s over-allotment option exercise.
• ·Warrants exercisable 30 days after initial business combination at $11.50 per share, expiring five years post-combination.
• ·Public warrants redeemable at $0.01 if Class A share price >= $18.00 for specified period.

07-04-2026

Kati Patang Lifestyle Limited filed a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on April 7, 2026, with BSE. Promoter Gokul Naresh Tandan declared that as on March 31, 2025, members of the Promoter & Promoter Group and persons acting in concert have not made any encumbrance of shares directly or indirectly during the financial year ended March 31, 2026. No encumbrances were reported.

• ·BSE Scrip Symbol: KATIPATANG, Scrip Code: 531126
• ·CIN: L72200DL1992PLC047931
• ·Registered Office: S-101, Panchsheel Park, New Delhi - 110017
• ·Corporate Office: 504, Savitri Cinema Complex, Greater Kailash-II, New Delhi-110048

07-04-2026

CKX Lands, Inc. filed a proxy statement for its 2026 Annual Meeting of Shareholders on May 7, 2026, seeking approval to elect six directors (Lee W. Boyer, Keith Duplechin, Daniel J. Englander, Max H. Hart, Lane T. LaMure, Eugene T. Minvielle IV), ratify MaloneBailey LLP as independent auditors, approve executive compensation on a non-binding advisory basis, and determine the frequency of future say-on-pay votes (recommending every year). As of April 3, 2026, 2,053,129 shares of common stock were outstanding, held by 256 record shareholders, with significant beneficial ownership by Ottley Properties, LLC (18.0% or 369,610 shares) and William Gray Stream (10.3% or 211,795 shares); no delinquent Section 16(a) reports were identified.

• ·Record date: March 26, 2026; only record holders entitled to vote.
• ·Quorum requires presence of majority of outstanding shares; election of directors by plurality vote.
• ·Broker non-votes have no effect on proposals; ratification of auditors (Item 2) considered routine.

07-04-2026

PlusAI announced a business update conference call on April 7, 2026, at 4:30 p.m. ET, to discuss commercial milestones including a live joint autonomous truck pilot with Ryder System, Inc. and International Motors on 600-mile routes, advancing SuperDrive™ toward 2027 L4 commercialization, and HyperFoundry™ launch with $25 million contracted value targeting $40–50 million full-year 2026 revenue. The company outlined a path to positive free cash flow in 2027 and readiness for public listing via merger with Churchill Capital Corp IX in Q2 2026. No historical performance data or declines were provided, only forward-looking targets.

• ·Merger with Churchill Capital Corp IX announced in June 2025; intended public listing in Q2 2026.
• ·Targeted 2027 commercial launch of SuperDrive™ for factory-built Level 4 autonomous trucks.
• ·Conference call webcast at https://plus.ai/investors; replay available through April 21, 2026.
• ·Operations headquartered in Silicon Valley with presence in US and Europe.

07-04-2026

NXG NextGen Infrastructure Income Fund issued a Notice of Guaranteed Delivery (EX-99.1) for its rights offering under the Prospectus Supplement dated April 6, 2026, and accompanying Prospectus dated July 9, 2025. The form facilitates subscription for common shares via primary subscription and over-subscription privilege, with submissions required by 5:00 p.m. ET on the Expiration Date of April 30, 2026, to Subscription Agent Equiniti Trust Company, LLC. No financial performance metrics or period comparisons are provided in the filing.

• ·Subscription delivery addresses: 55 Challenger Road, Suite #200, Ridgefield Park, New Jersey 07660, Attn: Reorganization Department
• ·Information Agent contact: (800) 207-2872
• ·Guaranteed delivery must be followed by Subscription Certificate by close of business on the first business day after Expiration Date

07-04-2026

The U.S. Bankruptcy Court for the Southern District of Texas confirmed the Fourth Amended Chapter 11 Plan of Liquidation for Luminar Technologies, Inc. and its four affiliated debtors on April 3, 2026, following a confirmation hearing on April 1, 2026, with all objections overruled. The debtors filed voluntary Chapter 11 petitions on December 15 and 31, 2025 (Case No. 25-90807), and have operated as debtors in possession since then. The plan proceeds to liquidation, marking a significant adverse development with no ongoing operations highlighted.

• ·Chapter 11 Cases jointly administered under Case No. 25-90807 (CML) in the Southern District of Texas Houston Division
• ·Creditors’ Committee appointed by U.S. Trustee on December 30, 2025
• ·Debtors’ mailing address: 2603 Discovery Drive, Suite 100, Orlando, Florida 32826
• ·Confirmation Hearing held April 1, 2026; Voting and Objection Deadline March 23, 2026

07-04-2026

Xponential Fitness, Inc. announced its Board of Directors has initiated a review of strategic alternatives to maximize shareholder value, potentially including a sale, merger, or other transaction, and engaged Jefferies LLC as financial advisor. Separately, the Board appointed Nicole Parent Haughey as an independent director, while Jair Clarke, Chelsea A. Grayson, and Bruce Haase stepped down from the Board. CEO Mike Nuzzo stated the team will continue executing its strategy amid the process.

• ·Operates franchise, master franchise, and international expansion agreements in 49 U.S. states, Puerto Rico, and 28 additional countries.
• ·Nicole Parent Haughey previously served as COO of Island Creek Oysters and Mimeo, and held roles at Vertical Research Partners, United Technologies, and Credit Suisse.
• ·References risks in Annual Report on Form 10-K for year ended December 31, 2025.

07-04-2026

Opus Genetics announced a strategic financing agreement with Oberland Capital providing up to $155 million in non-dilutive funding via notes, including an initial $35 million tranche and a concurrent $5 million equity investment at $4.48 per share, boosting current cash to approximately $100 million and extending the runway into 2029 to fund pivotal studies for OPGx-LCA5 and OPGx-BEST1. The deal supports accelerating three earlier-stage programs—OPGx-RDH12 (clinic Q4 2026), OPGx-MERTK (end 2026), and OPGx-RHO (2027)—with topline results from OPGx-BEST1 Phase 1/2 Cohort 1 on track for mid-2026. No declines or flat metrics reported; financing terms include 7-year maturity, ~4.1% initial cash interest rate, and partial convertibility.

• ·Initial closing expected April 20, 2026; notes mature 7 years from issuance with 6-year interest-only period and 50% repayment on 6th anniversary.
• ·Notes: floating rate with floor/cap; 50% interest paid-in-kind first 8 quarters; up to 10% principal convertible at $6.72/share.
• ·Additional $35M tranche available on or prior to March 31, 2028 upon LCA5 regulatory milestones.
• ·RDH12 partially funded by RDH12 Alliance; MERTK collaboration with Department of Health - Abu Dhabi.

07-04-2026

Starton Holdings, Inc., a clinical-stage biotechnology company focused on continuous delivery technologies for cancer treatments targeting hematologic malignancies, filed Amendment No. 3 to its S-1 registration statement for an initial public offering of 6,666,667 shares of common stock priced between $5.00 and $7.00 per share, with plans to list on Nasdaq Capital Market under the symbol 'STA'. The underwriters have a 45-day option to purchase up to 1,000,000 additional shares to cover over-allotments. As an emerging growth company and smaller reporting company, it emphasizes high investment risk and reduced reporting requirements.

• ·Filing date: April 7, 2026 (as filed with SEC on April 6, 2026)
• ·SEC file number: 333-292059
• ·Principal executive offices: 215 College Road, Suite 300, Paramus, NJ 07652
• ·Fiscal year end: March 31
• ·EIN: 33-2448745
• ·Standard Industrial Classification: Pharmaceutical Preparations [2834]
• ·Estimated IPO price per share: $5.00 to $7.00

07-04-2026

APEX Tech Acquisition Inc., a SPAC, reported a net loss of $39,322 for the three months ended February 28, 2026, a 371% worsening from the $8,349 loss in the prior three-month period, and a total net loss of $47,671 for the six months ended February 28, 2026. The company successfully completed its IPO, depositing $111,971,310 into the Trust Account from public units and adding $2,089,710 from private units, resulting in total assets of $112,555,390, up dramatically from $28,000 at August 31, 2025. Cash balance increased to $584,080, while shareholders' equity rose to $584,080 from $7,953 over the same period.

• ·Underwriter’s partial exercise of over-allotment option to purchase 1,197,131 units on February 27, 2026, resulting in 299,283 ordinary shares no longer subject to forfeiture.
• ·Forfeiture of 75,717 founder shares during the period.
• ·Sponsor retroactively increased purchase of ordinary shares from 1,725,000 to 2,875,000 for $25,000.
• ·Net cash used in operating activities: $39,671 for six months ended February 28, 2026.

07-04-2026

Flushing Financial Corporation's stockholders overwhelmingly approved the merger proposal with OceanFirst Financial Corp. at a special meeting on April 2, 2026, with 24,102,136 votes in favor (97.3% of shares represented), 628,640 against, and 40,182 abstentions out of 24,770,958 shares represented (73.1% quorum of 33,883,626 outstanding shares). However, the advisory compensation proposal for named executive officers passed narrowly with 12,435,187 votes for (50.2%) versus 12,222,100 against and 113,671 abstentions. Under the merger terms, each Flushing share will convert to 0.85 shares of OceanFirst common stock.

• ·Joint press release issued April 6, 2026, announcing voting results.
• ·Merger involves two-step process: Merger Sub into Flushing, then Flushing into OceanFirst.
• ·OceanFirst stockholder meeting also held April 2, 2026.
• ·Proposed Warburg Pincus investment in OceanFirst equity securities.

07-04-2026

Velo3D, Inc. appointed James Suva as Chief Financial Officer and principal financial and accounting officer, effective April 6, 2026, as previously disclosed on March 20, 2026. Under the offer letter effective March 5, 2026, Mr. Suva receives an annual base salary of $380,000 and a target bonus for fiscal 2026 equal to 70% of his base salary. The Compensation Committee granted 135,000 RSUs vesting 25% on May 15, 2027, and 1/16th quarterly thereafter subject to continued service.

• ·Offer letter entered April 6, 2026, effective March 5, 2026; at-will employment with customary confidentiality covenants
• ·RSU vesting on Quarterly Vest Dates: February 15, May 15, August 15, November 15
• ·Offer letter filed as Exhibit 10.1

07-04-2026

Protagenic Therapeutics, Inc. notified Alexander Arrow, MD, its Chief Financial Officer, that his employment will be terminated effective April 30, 2026, with the board notification occurring on March 31, 2026. No replacement has been announced, representing a key leadership transition. The filing was signed by Executive Chairman Garo H. Armen.

• ·Filing signed on April 6, 2026, and dated April 7, 2026

07-04-2026

At the April 2, 2026 special stockholder meeting, OceanFirst Financial Corp. shareholders approved the issuance proposal for common stock to Flushing Financial Corporation merger holders and Warburg Pincus affiliates (42,020,260 for, 2,526,694 against, 176,895 abstentions), representing a strong endorsement of the merger and investment. However, the charter amendment to exempt Warburg from certain ownership restrictions was rejected (18,408,853 for, 26,148,179 against, 166,817 abstentions), potentially complicating the transaction. A quorum was met with 44,723,849 shares present out of 57,402,016 outstanding.

• ·Record date for special meeting: February 20, 2026
• ·Joint proxy statement/prospectus dated February 26, 2026
• ·Joint press release issued April 6, 2026 announcing voting results

07-04-2026

Four Corners Property Trust (NYSE: FCPT) entered into a new seven-year $200 million senior unsecured delayed draw term loan facility maturing on April 6, 2033, with $50 million drawn at close for immediate investments and general corporate purposes, and the remaining $150 million available for future acquisitions expected in late Q2 and early Q3 2026. The facility is priced at 1.25% over SOFR, supported by BBB/Baa3 ratings, with 96% of term loans hedged and overall debt 98% fixed-rate through November 2027; pro forma run-rate leverage is approximately 5.4x within the 5.0x-6.0x target range. Executives highlighted the attractive pricing and flexibility for accretive investments at 200+ basis points spreads.

• ·Term Loan Facility credit margin: 1.25% over SOFR.
• ·Maturity date: April 6, 2033.
• ·Current senior unsecured debt ratings: BBB (Fitch) / Baa3 (Moody’s).
• ·Stated net leverage range: 5.0x-6.0x.
• ·Facility led by The Huntington National Bank as Administrative Agent.

07-04-2026

EVERTEC, Inc.'s 2026 Proxy Statement for the May 21, 2026 virtual annual meeting highlights record revenue in 2025, the Q4 acquisition of Tecnobank in Brazil, and business diversification with more than 40% of revenues now generated outside Puerto Rico. Latin America showed robust growth from organic expansion and integrations, while Puerto Rico delivered steady performance amid favorable conditions and ATH Móvil adoption; the company managed headwinds through cost discipline. Stockholders will vote on electing 10 director nominees, an advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as auditors for 2026.

• ·Annual Meeting: May 21, 2026, 9:00 a.m. Atlantic Standard Time, virtual at www.virtualshareholdermeeting.com/EVTC2026
• ·Record Date: March 27, 2026
• ·Director nominees: Frank G. D’Angelo, Morgan M. Schuessler, Jr., Kelly Barrett, Olga Botero, Virginia Gambale, Jorge A. Junquera, Iván Pagán, Aldo J. Polak, Alan H. Schumacher, Brian J. Smith

07-04-2026

Cell Source, Inc. (CLCS) 10-K filing highlights severe financial risks, including a history of operating losses, substantial doubt about continuing as a going concern, defaults on promissory notes, and the need for additional financing. The company, an early-stage biotech with an unproven strategy, faces stock-related risks such as illiquid trading, insider voting concentration, dilution from future issuances, and penny stock status. No positive financial or operational metrics are presented, emphasizing ongoing challenges in clinical development and commercialization.

• ·Licensing milestones: Commence Phase 2 clinical trials by January 1, 2028 (with interim research sponsorship); commence Phase 3 or receive FDA/EMA Marketing Approval by January 1, 2031; First Commercial Sale within 12 months of Marketing Approval; no sales for 12+ months post-commencement triggers potential termination.
• ·License terms: Exclusive worldwide license under Licensed Information and Patents until later of last Patent expiration or 15-year period from FDA New Drug Approval; 'Orphan Drug' status extends coverage.
• ·Patent obligations: Company bears costs for infringement litigation and indemnifies Yeda.

07-04-2026

Green Stream Holdings Inc. reported changes in control via officer and director transitions: James C. DiPrima resigned as an officer on March 17, 2026, and as a director on March 19, 2026, while Phil Yang was appointed as Vice President, Chief Executive Officer, Secretary, Treasurer, and Director on March 18, 2026, owning no shares. The company redomiciled from Wyoming to California. No financial impacts or performance metrics were disclosed.

• ·Phil Yang's professional background includes overseeing mortgage processing at Direct Mortgage Investors, Inc. (2019-2023), private mortgage loans, and recent commercial asset acquisitions in Rochester, NY, and Washington DC.
• ·Phil Yang holds BA in Government and International Politics, BS in Public Administration (George Mason University, 2016), and MA in International Security (George Washington University, 2018).

07-04-2026

CVB Financial Corp.'s definitive proxy statement (DEF 14A) dated April 7, 2026, outlines the 2026 annual shareholder meeting on May 20, 2026, at 8:00 a.m. PDT in Ontario, CA, with proposals to elect 10 directors (or 8 if the proposed merger with Heritage Commerce Corp is not completed), approve on an advisory basis the 2025 named executive officer compensation, and ratify KPMG LLP as independent auditors for 2026. Continuing director nominees include George A. Borba, Jr., Jane Olvera Majors, David A. Brager, Raymond V. O’Brien III, Stephen A. Del Guercio, Hal W. Oswalt, Anna Kan, and Timothy Stephens; contingent nominees are Julianne Biagini-Komas and R. Clay Jones. The record date for voting eligibility is March 26, 2026.

• ·Meeting location: CVB Financial Corp. Corporate Headquarters, 701 North Haven Avenue, Ontario, CA 91764.
• ·Audio conference call access: Dial 1 (833) 630-1956; replay access code 1160694 until May 27, 2026.
• ·Proxy materials available at https://investors.cbbank.com/annual-meeting.

07-04-2026

On April 1, 2026, Partners Group Lending Fund, LLC entered into an Amended and Restated Expense Support and Conditional Reimbursement Agreement with Partners Group (USA) Inc., amending the original agreement from August 31, 2023, by changing the Expense Limitation for Other Operating Expenses to 1.00% (annualized) of the Fund's net asset value instead of Aggregate Capital Commitments. The Adviser will waive the Base Management Fee and pay or absorb expenses to meet this cap, with the Fund required to reimburse waived amounts over up to three years if it remains in compliance. The agreement has a one-year term and automatically renews annually unless terminated with 30 days' notice.

• ·Agreement terminates automatically upon termination of Investment Advisory Agreement, Fund dissolution/liquidation, or public listing/liquidity event.
• ·Reimbursement must not cause Fund to exceed Expense Limitation and is extinguished after three years if not repaid.
• ·Unitholders are third-party beneficiaries with enforcement rights.

07-04-2026

Nuveen Churchill Direct Lending Corp. (NCDL) filed a DEF 14A proxy statement for its virtual annual shareholder meeting on May 21, 2026, at 12:30 p.m. ET, to elect Kenneth Kencel and Stephen Potter as directors for terms expiring at the 2029 annual meeting. The record date is March 31, 2026, with 49,387,065 common shares (par value $0.01 per share) outstanding and entitled to vote. Shareholders are encouraged to vote via internet, phone, or mail by May 20, 2026, 11:59 p.m. ET.

• ·Meeting held virtually via live audio webcast at www.virtualshareholdermeeting.com/NCDL2026; control number required to vote or ask questions.
• ·Proxy materials and Form 10-K for fiscal year ended December 31, 2025 available at www.virtualshareholdermeeting.com/NCDL2026, www.proxyvote.com, www.ncdl.com, and SEC EDGAR.
• ·Quorum requires majority of outstanding shares; Proposal 1 (director election) requires plurality of votes cast, no broker discretionary voting.

07-04-2026

Cambium Networks Corp reported total revenues of $177,286 thousand for 2024, down 21.8% YoY from $226,767 thousand in 2023 (restated), with sharp declines in Point-to-Multi-Point (-23.3%) and Point-to-Point (-40.8%) segments offsetting growth in Enterprise (+13.3%); geographically, North America fell 37.4% while EMEA rose 16.7%. Gross profit margin improved to 35.5% from 33.9%, driven by better subscriptions and services margins (57.9% vs 53.8%), but operating expenses rose 2.1% to $133,342 thousand due to a $25,535 thousand impairment, widening operating loss to $(70,411) thousand from $(53,820) thousand. Net loss was stable at $(74,452) thousand versus $(74,080) thousand in 2023.

• ·R&D expenses decreased 26.5% YoY to $39,292 thousand.
• ·Sales and marketing expenses fell 14.4% YoY to $36,719 thousand.
• ·Interest expense, net rose 131.8% YoY to $5,843 thousand.
• ·Effective income tax rate improved to 2.4% from (30.9)%.

07-04-2026

The Marcus Corporation (MCS) filed its DEF 14A proxy statement on April 7, 2026, for the 2026 Annual Meeting of Shareholders on May 21, 2026, held virtually at www.virtualshareholdermeeting.com/MCS2026. Shareholders will vote on electing 12 director nominees, approving (advisory) named executive officer compensation, and ratifying Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026. The record date is March 24, 2026, with 23,753,627 Common Shares (1 vote each) and 6,984,584 Class B Shares (10 votes each) outstanding, totaling 93,599,467 votes.

• ·Proxy materials available at www.proxyvote.com; requests for paper copies by May 7, 2026.
• ·Brokers cannot vote uninstructed shares on director elections or say-on-pay.
• ·XBRL tags indicate disclosure of PEO and Non-PEO NEO compensation elements (stock awards, option awards, pension values, equity fair value changes) for fiscal years 2021-2025, but specific numerical values not provided in filing excerpt.

07-04-2026

Jaguar Health, Inc. reported total revenue of $11,511 thousand in 2025, down 1.5% YoY from $11,689 thousand, with net product revenue declining 1.9% to $11,339 thousand amid flat Mytesi sales (-1.4%) and Canalevia drop (-7.5%), offset by Gelclair growth of 185.7%. Operating expenses surged 35.0% to $57,419 thousand, driven by R&D up 50.9%, cost of product revenue up 93.0%, leading to operating loss widening to $45,908 thousand (up 48.9%) and net loss to $53,997 thousand (up 37.6% YoY). Cash used in operations improved to $23,686 thousand from $29,384 thousand, but net cash decreased by $170 thousand.

• ·Gross product sales total $15,325 thousand in 2025, down 0.8% YoY from $15,455 thousand.
• ·Cash used in operating activities $23,686 thousand in 2025 vs $29,384 thousand in 2024.
• ·Impairment loss on indefinite-lived intangible assets $800 thousand in 2025 (none in 2024).
• ·Net increase (decrease) in cash and restricted cash $(170) thousand in 2025 vs $1,533 thousand in 2024.

07-04-2026

SKIL Infrastructure Limited (CIN: L36911MH1983PLC178299), under Corporate Insolvency Resolution Process (CIRP) pursuant to Hon’ble NCLT Mumbai order dated 1st February 2024, with Purusottam Behera as Resolution Professional, has provided pre-facto intimation of its Fifth Committee of Creditors (COC) meeting scheduled for April 08, 2026, at 11:00 A.M. via virtual audio-visual means. This disclosure complies with Regulation 30 and Schedule III of SEBI (LODR) Regulations, 2015, to NSE (Symbol: SKIL) and BSE (Scrip Code: 539861). The ongoing CIRP indicates continued financial distress with no resolution updates provided.

• ·RP IBBI Registration No: IBBI/IPA-002/IP-N00940/2019-20/12993 (AFA valid till 31st December 2026).
• ·RP Address: Flat No. 402, Sai Prasad Building, Sion Kamgar CHS, Road No- 29, Sion (East), Mumbai, Maharashtra, 400022.
• ·Contact: cirpskil@gmail.com, +917718851633.

07-04-2026

Promoters of Cinevista Limited, including Sunil Mehta, disclosed under SEBI (SAST) Regulation 31(4) that no encumbrances were made directly or indirectly on their shares during the financial year ended March 31, 2026. They confirmed that nil shares are encumbered or pledged as of that date. This filing provides reassurance of no changes in promoter share encumbrances.

• ·Disclosure covers financial year ended March 31, 2026
• ·Filing date: April 7, 2026
• ·Applies to Promoters/Promoters Group/Person Acting in Concert (PAC)

07-04-2026

Jagsonpal Services Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate from MAS Services Limited confirms that securities received for dematerialization from January 1, 2026, to March 31, 2026, were processed (accepted/rejected) within 15 days, certificates mutilated and cancelled, registers updated, and notifications sent to depositories and stock exchanges within the required timelines.

• ·Period covered: January 1, 2026 to March 31, 2026
• ·Scrip Code: 530601/JAGSONSER
• ·CIN: L62010MH1991PLC467067

07-04-2026

GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota on April 3, 2026, under which the University will sponsor an IND application (IND 169118) for GTB-5550 and conduct a phase 1a/1b clinical trial titled 'GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy.' The Company will bear the costs of up to approximately $3.8 million over three years for the study, with both parties having rights to publish results and standard termination provisions including 30 days' notice or immediate for safety reasons.

• ·IND number: 169118
• ·Agreement termination: 30 days' written notice, immediate by University for health/safety, or for material breach uncured within 30 days

07-04-2026

Bread Financial Holdings, Inc. filed its 2026 DEF 14A Proxy Statement for the virtual annual stockholder meeting on May 19, 2026 (record date March 25, 2026), recommending votes FOR the election of director nominees, advisory approval of executive compensation, approval of the 2026 Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as auditor. 2025 business highlights from continuing operations included net income of $521M (87% YoY increase vs. 2024) and diluted EPS of $10.96 (98% YoY increase vs. 2024); no declines or flat metrics were highlighted.

• ·Virtual annual meeting at 10:00 a.m. Eastern Time via www.proxydocs.com/BFH; advance registration required with control number.
• ·Proxy materials first mailed on or about April 7, 2026.
• ·No specific numeric values provided for compensation components (e.g., equity awards, pensions) for PEO or Non-PEO NEOs across 2021-2025.